Regulating the effects of GPR21, a novel target for type 2 diabetes
- S. Leonard; G. K. Kinsella; E. Benetti; J. B. Findlay Regulating the effects of GPR21, a novel target for type 2 diabetes Scientific reports
Insulin Resistance & Diabetes
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- I. Lingvay; A. M. Catarig; J. P. Frias; H. Kumar; N. L. Lausvig; C. W. le Roux; D. Thielke; A. Viljoen; R. J. McCrimmon Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial The Lancet Diabetes and Endocrinology
Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2
- C. Le Roux; A. Aminian; R. Batterham; D. Hesse; C. Jensen; B. McGowan; A. Pakseresht; G. Rigas Sydney; F. Rubino; S. Taheri; et al. Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2 Obesity (Silver Spring, Md.)
Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m2: A Post-hoc Analysis
- C. Le Roux; V. Aroda; J. Hemmingsson; A. P. Cancino; R. Christensen; X. Pi-Sunyer Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m2: A Post-hoc Analysis Obesity Facts
Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial
- C. W. Le Roux; A. Astrup; F. Greenway; M. Krempf; R. Vettor; L. Shapiro Manning; S. K. Lilleore; K. Fujioka Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial Diabetologia
Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes
- C. W. Le Roux; D. C. W. Lau; K. Fujioka; F. Greenway; J. P. H. Wilding; P. B. Jacobsen; T. Skjoth; S. Madsbad Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes Diabetic medicine
Liraglutide; A new hope for obese diabetics
- A. Kumar; D. Kumar; S. Razzaque; A. Kumar; R. Kumar; M. I. Ghauri; M. Yaseen Liraglutide; A new hope for obese diabetics Journal of the Liaquat University of Medical and Health Sciences
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- C. W. le Roux; A. Astrup; K. Fujioka; F. Greenway; D. C. W. Lau; L. Van Gaal; R. V. Ortiz; J. P. H. Wilding; T. V. Skjøth; L. S. Manning; X. Pi-Sunyer 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet
Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
- A. Kokkinos; D. Tsilingiris; C. W. le Roux; F. Rubino; C. S. Mantzoros Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery? Metabolism
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
- D. S. Feig; L. E. Donovan; B. Zinman; J. J. Sanchez; E. Asztalos; E. A. Ryan; I. G. Fantus; E. Hutton; A. B. Armson; L. L. Lipscombe; D. Simmons; J. F. R. Barrett; P. J. Karanicolas; S. Tobin; H. D. McIntyre; S. Y. Tian; G. Tomlinson; K. E. Murphy; D. Fei Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial The Lancet Diabetes and Endocrinology